VF
KTTA icon

Virtu Financial’s Pasithea Therapeutics KTTA Stock Holding History

Virtu Financial’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,075
Closed -$18K – 1961
2025
Q3 		$18K Buy
+25,075
New +$18.3K ﹤0.01% 1290
2023
Q4 		– Sell
-773
Closed -$7K – 1795
2023
Q3 		$7K Sell
773
-73
-9% -$799 ﹤0.01% 1130
2023
Q2 		$8K Buy
846
+103
+14% +$831 ﹤0.01% 1370
2023
Q1 		$6K Sell
743
-804
-52% -$9.09K ﹤0.01% 1383
2022
Q4 		$20K Buy
+1,547
New +$30.9K ﹤0.01% 1272
2022
Q3 		– Sell
-729
Closed -$15K – 1982
2022
Q2 		$15K Buy
+729
New +$15.5K ﹤0.01% 1376

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Virtu Financial's KTTA Position: Q4 2025 in Review

Virtu Financial sold out of Pasithea Therapeutics (KTTA) in Q4 2025, closing a stake of 25,075 shares — an estimated $18K sold.

Virtu Financial first reported a position in KTTA in Q2 2022 and held it in 6 quarters. The position peaked at $20K in Q4 2022. 26 funds tracked by Wall St. Rank hold KTTA as of Q4 2025.

  • Virtu Financial reported no remaining Pasithea Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Virtu Financial sold 25,075 Pasithea Therapeutics shares in Q4 2025, an estimated $18K.
  • Virtu Financial first reported a position in Pasithea Therapeutics in Q2 2022 and held it in 6 quarters.
  • Virtu Financial's Pasithea Therapeutics position peaked at $20K in Q4 2022.
  • 26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.